Glycorex Transplantation AB (FRA:O33) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O33 Glycorex Transplantation AB FRA:O33
61 GF Score
Price €0.09
GF Value €0.14
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Glycorex Transplantation AB Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:O33
61GF Score
Glycorex Transplantation AB FRA:O33
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?

Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued. The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14. GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.

Key valuation signals for FRA:O33:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glycorex Transplantation AB Business Description

Other Exchanges GTAB B:Sweden
Address Scheelevagen 27, Lund, SWE, 223 63
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score

Get the complete analysis for FRA:O33

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.14
GF Value